Compare

Ambu A/S/€AMBUB

1D1W1M3M6MYTD1Y5YMAX

About Ambu A/S

Ambu A/S is a Danish company operating in the medical device industry, primarily involved in the development, manufacturing, and marketing of innovative healthcare solutions. The company's key products include single-use endoscopes, anesthesia devices, and patient monitoring and diagnostic solutions. Ambu was founded in 1937 and is headquartered in Ballerup, Denmark. It is known for its focus on single-use devices, which help reduce the risk of cross-contamination and improve efficiency in hospitals and clinics worldwide. The company's strategic positioning emphasizes innovation in medical technology and a strong commitment to addressing healthcare challenges globally.
Ticker
€AMBUB
Sector
Health
Primary listing
XGAT
Employees
5,200
Headquarters
Ballerup, Denmark
Website
www.ambu.com

Ambu A/S Metrics

BasicAdvanced
€3.1B
45.49
€0.26
1.39
€0.05
0.47%

What the Analysts think about Ambu A/S

Analyst ratings (Buy, Hold, Sell) for Ambu A/S stock.
Analyst projections of the future price of Ambu A/S stock.

Bulls say / Bears say

Q4 organic revenue growth accelerated to 13.9%, with Endoscopy Solutions up 21.2%, showing strong momentum in Ambu’s main growth engine. The company expects Endoscopy to grow around 15% in FY 2026/27. (Ambu A/S)
New US and European clearances let Ambu use its single-use GI scopes for lower-GI procedures as well as upper-GI procedures, nearly doubling the number of GI procedures it can target. The expanded products are planned for commercial launch in early 2027. (Ambu A/S)
The TIMS Medical acquisition adds hospital workflow and imaging software, access to about 7,000 US hospital installations and around USD 15m in expected annual revenue. Ambu says the deal should add to revenue growth and can support wider sales of its endoscopy offering. (Ambu A/S)
Ambu’s FY 2026/27 EBIT margin guidance of 13–15% is below analyst expectations of 15.4%, raising the risk of earnings downgrades. Cash conversion was around 30%, below the company’s target of more than 40%, as investment spending rises. (Inderes, Ambu A/S)
Ambu is facing tougher competition in urology, and its ureteroscope launch has gained market share more slowly than expected. UBS also sees the product pipeline as unlikely to make a material contribution until later in the decade, which could constrain growth. (Investing.com)
Anesthesia and Patient Monitoring remain a drag: the division grew only 2.8% in Q4, while Anesthesia sales fell 0.6%. Weakness in this part of the business leaves Ambu more reliant on endoscopy to deliver group growth. (Ambu A/S)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.

Ambu A/S Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Ambu A/S Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Ambu A/S

AllEURUSDGBP
Funds
Fund name
Fund size
€AMBUB weighting
Vanguard ESG Developed Europe All Cap£V3EA
€125M0.02%
Vanguard ESG Developed Europe All Cap£V3EL
€35M0.02%
Vanguard ESG Global All Cap$V3AA
$1.1B0.00%
Vanguard ESG Global All Cap£V3AM
$678M0.00%
Vanguard ESG Global All Cap£V3AB
$1.1B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.